AstraZeneca (LSE:AZN) is navigating a period of robust growth and strategic challenges. Recent developments include an 18% ...

Two of the world’s biggest drugmakers — AstraZeneca and MSD — have hailed progress in tackling hard-to-treat cancers, ...

As FDA takes up Dato-Dxd, AstraZeneca's David Fredrickson places next ADC bet on in-house pipeline The question then moves to whether the biomarker test would be too cumbersome for doctors ...

WebMD, March 2023 The 4 Ps of Cancer Care: Policy, Politics, Priorities, and Prevention AstraZeneca's David Fredrickson is encouraged by the latest cancer research and discusses the four Ps ...

AstraZeneca has shared an early look at the performance of its in-house antibody-drug conjugate (ADC) technology, publishing phase 1 data on candidates that could compete with molecules from ...

David Muir has encountered a whirlwind of attention over the past week since acting as one of the moderators for the presidential debate between Vice President Kamala Harris and former President ...

British pharma giant AstraZeneca plans to spend $135 million to expand the manufacturing operations footprint of its site in Södertälje, Sweden, by 50%. The project calls for a 2,700-square ...

Welcome, ladies and gentlemen, to AstraZeneca's Investor Conference Call ESMO 2024. Before I hand over to AstraZeneca's management team, I'd like to read the safe harbor statement. The Company ...

This is the online edition of ESMO in 30 Seconds, a pop-up newsletter from the European Society for Medical Oncology’s annual meeting in Barcelona, Spain. Sign up for the remaining editions here.